Ligand stabilization enables physiological GITR signaling and antitumor immunity
Admasu, T.; Sadanala, K.; Kalyane, D.; Wang, H.; Yoon, S.; WooHyun, K.; Katiki, M.; Rudnick, J.; Ramachandran, M.; Yu, J.
Show abstract
Agonistic antibodies targeting the costimulatory receptor GITR have failed in clinical trials despite a strong preclinical rationale, revealing fundamental limitations of receptor-targeted approaches to TNF superfamily agonism. Here, we demonstrate that pharmacological stabilization of the trimeric structure of human GITRL represents a mechanistically distinct strategy to overcome these limitations. Small-molecule stabilization of GITRL preserves its membrane residency. It enables bidirectional signaling between antigen-presenting cells and T cells, a physiological context that receptor-targeted antibodies bypass through non-physiological clustering of GITR. In humanized GITR/GITRL double-knock-in mice bearing syngeneic tumors, GITRL stabilization expands cytotoxic CD8 T cells, selectively depletes intratumoral regulatory T cells, activates APCs, and restructures the immune spatial architecture. In patient-derived tumor explants, GITRL stabilization reactivates suppressed CD8 T cells in an APC-dependent manner. Our findings establish ligand stabilization as a mechanistically distinct therapeutic strategy and provide a framework for engaging TNF receptor superfamily costimulatory pathways by modulating their native ligands.
Matching journals
The top 7 journals account for 50% of the predicted probability mass.
Similar papers in this journal
Similar papers in this journal
- An mRNA-encoded, long-lasting Interleukin-2 restores CD8+ T cell neoantigen immunity in MHC class I-deficient cancers 97%
- MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors 97%
- Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer 96%
Similar papers in this journal
Similar papers in this journal
- Cell lineage as a predictor of immune response in neuroblastoma 96%
- Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance 94%
- Cancer-associated fibroblast compositions change with breast cancer progression linking S100A4 and PDPN ratios with clinical outcome 94%
Similar papers in this journal
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.